A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders (iNCGS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by Ipsen
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: April 3, 2007
Last updated: June 29, 2015
Last verified: June 2015
This study is a multicenter, open label, observational, post marketing surveillance study of NutropinAq® in France, Germany, Italy, Spain, Romania and United Kingdom

Condition Phase
Growth Hormone Disorders
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: International Cooperative Growth Study (iNCGS) Post Marketing Surveillance Program for NutropinAq® [Somatropin (rDNA Origin) Injection]

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Number of participants with adverse events [ Time Frame: Every 3 months until study completion ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Post-treatment height measurements until epiphyseal closure is achieved. [ Time Frame: Every 3 months until study completion ] [ Designated as safety issue: No ]

Estimated Enrollment: 5250
Study Start Date: June 2006
Estimated Study Completion Date: December 2099
Estimated Primary Completion Date: December 2099 (Final data collection date for primary outcome measure)
Detailed Description:
The objective of this study is to collect long term safety and efficacy information on Ipsen's growth hormone (GH) NutropinAq® regarding treatment of paediatric growth disorders for which GH is indicated

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children treated with NutropinAq in the specialised paediatric endocrinology centres

Inclusion Criteria:

  • Children of either sex who are treated with NutropinAq® for the treatment of growth failure
  • Patients who are willing to comply with follow-up appointments throughout study participation
  • Written informed consent signed by both parents or by the liable parent or by the legal guardian when applicable, and by the child when applicable

Exclusion Criteria:

  • Patients not treated with NutropinAq®
  • Patients with closed epiphyses
  • Patients with active neoplasia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00455728

Contact: Ipsen Recruitment Enquiries clinical.trials@ipsen.com

United Kingdom
Ipsen Central Contact Recruiting
Slough, Berkshire, United Kingdom, SL1 3XE
Contact       clinical.trials@ipsen.com   
Sponsors and Collaborators
Study Director: Caroline Sert, MD Ipsen
  More Information

No publications provided

Responsible Party: Ipsen
ClinicalTrials.gov Identifier: NCT00455728     History of Changes
Other Study ID Numbers: 2-79-58035-005
Study First Received: April 3, 2007
Last Updated: June 29, 2015
Health Authority: France: French Data Protection Authority
Germany: Federal Institute for Drugs and Medical Devices
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Italy: Ministry of Health
Spain: Spanish Agency of Medicines
Romania: Ethics Committee
Romania: National Agency for Medicines and Medical Devices

ClinicalTrials.gov processed this record on November 30, 2015